| Avalon Place | |
| 3410 W. Pittsburgh Rd, New Castle, Pennsylvania 16101 | |
| (724) 658-4781 | |
| Name | Avalon Place |
|---|---|
| Location | 3410 W. Pittsburgh Rd, New Castle, Pennsylvania |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 84 |
| Occupancy Rate | 71.9% |
| Medicare ID (CCN) | 396075 |
| Legal Business Name | South Central Alpha Housing & Healthcare Inc |
| Ownership Type | Non Profit - Corporation |
| NPI Number | 1215798541 |
| Organization Name | AVA OPCO LLC |
| Address | 3410 W Pittsburg Rd, New Castle, PA 16101 |
| Phone Number | 516-447-5923 |
News Archive
Researchers have developed a new model to analyze tissue engineered cartilage that allows for the use of a single method to assess functional tissue mechanics in cartilage constructs at all stages of development from the laboratory through large animal testing.
A Faculty of 1000 evaluation examines how a stomach-produced hormone that influences the desire to eat and consume alcohol could be switched off to control drinking problems.
John Lachin, professor of biostatistics, epidemiology and statistics at the George Washington University, has been awarded a five-year, $134 million grant from the National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases to conduct a clinical trial examining the long-term effectiveness of several glucose-lowering medications for treatment of people with type 2 diabetes. The grant sets a record as the largest sum award GW has ever received.
Johns Hopkins scientists were dubious in the early 1980s when they stumbled on small sugar molecules lurking in the centers of cells; not only were they not supposed to be there, but they certainly weren't supposed to be repeatedly attaching to and detaching from proteins, effectively switching them on and off.
VIVUS, Inc. today announced that additional data on Qnexa(TM), an investigational drug candidate for obesity, was presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley W. Day, PhD, vice president of clinical development at VIVUS, presented the additional data from the company's two year-long phase 3 obesity trials during the Pharmacotherapy Update portion of the pre-conference on October 24, 2009.
› Verified 8 days ago
| NPI Number | 1679674733 |
| Organization Name | SOUTH CENTRAL ALPHA HOUSING & HEALTHCARE INC. |
| Doing Business As | AVALON PLACE |
| Address | 3410 W Pittsburg Rd, New Castle, PA 16101 |
| Phone Number | 724-658-4781 |
News Archive
Researchers have developed a new model to analyze tissue engineered cartilage that allows for the use of a single method to assess functional tissue mechanics in cartilage constructs at all stages of development from the laboratory through large animal testing.
A Faculty of 1000 evaluation examines how a stomach-produced hormone that influences the desire to eat and consume alcohol could be switched off to control drinking problems.
John Lachin, professor of biostatistics, epidemiology and statistics at the George Washington University, has been awarded a five-year, $134 million grant from the National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases to conduct a clinical trial examining the long-term effectiveness of several glucose-lowering medications for treatment of people with type 2 diabetes. The grant sets a record as the largest sum award GW has ever received.
Johns Hopkins scientists were dubious in the early 1980s when they stumbled on small sugar molecules lurking in the centers of cells; not only were they not supposed to be there, but they certainly weren't supposed to be repeatedly attaching to and detaching from proteins, effectively switching them on and off.
VIVUS, Inc. today announced that additional data on Qnexa(TM), an investigational drug candidate for obesity, was presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley W. Day, PhD, vice president of clinical development at VIVUS, presented the additional data from the company's two year-long phase 3 obesity trials during the Pharmacotherapy Update portion of the pre-conference on October 24, 2009.
› Verified 8 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Researchers have developed a new model to analyze tissue engineered cartilage that allows for the use of a single method to assess functional tissue mechanics in cartilage constructs at all stages of development from the laboratory through large animal testing.
A Faculty of 1000 evaluation examines how a stomach-produced hormone that influences the desire to eat and consume alcohol could be switched off to control drinking problems.
John Lachin, professor of biostatistics, epidemiology and statistics at the George Washington University, has been awarded a five-year, $134 million grant from the National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases to conduct a clinical trial examining the long-term effectiveness of several glucose-lowering medications for treatment of people with type 2 diabetes. The grant sets a record as the largest sum award GW has ever received.
Johns Hopkins scientists were dubious in the early 1980s when they stumbled on small sugar molecules lurking in the centers of cells; not only were they not supposed to be there, but they certainly weren't supposed to be repeatedly attaching to and detaching from proteins, effectively switching them on and off.
VIVUS, Inc. today announced that additional data on Qnexa(TM), an investigational drug candidate for obesity, was presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley W. Day, PhD, vice president of clinical development at VIVUS, presented the additional data from the company's two year-long phase 3 obesity trials during the Pharmacotherapy Update portion of the pre-conference on October 24, 2009.
› Verified 8 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $975 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 3.9 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 14.35 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 56.86 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.58 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.7 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 6.45 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.79 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 13.45 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 89.03 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 4.62 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 15.58 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 4.46 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.39 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 98.32 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 71.43 | 82.93 |
News Archive
Researchers have developed a new model to analyze tissue engineered cartilage that allows for the use of a single method to assess functional tissue mechanics in cartilage constructs at all stages of development from the laboratory through large animal testing.
A Faculty of 1000 evaluation examines how a stomach-produced hormone that influences the desire to eat and consume alcohol could be switched off to control drinking problems.
John Lachin, professor of biostatistics, epidemiology and statistics at the George Washington University, has been awarded a five-year, $134 million grant from the National Institute of Health's National Institute of Diabetes and Digestive and Kidney Diseases to conduct a clinical trial examining the long-term effectiveness of several glucose-lowering medications for treatment of people with type 2 diabetes. The grant sets a record as the largest sum award GW has ever received.
Johns Hopkins scientists were dubious in the early 1980s when they stumbled on small sugar molecules lurking in the centers of cells; not only were they not supposed to be there, but they certainly weren't supposed to be repeatedly attaching to and detaching from proteins, effectively switching them on and off.
VIVUS, Inc. today announced that additional data on Qnexa(TM), an investigational drug candidate for obesity, was presented at the 27th annual scientific meeting of The Obesity Society (TOS) in Washington D.C. Wesley W. Day, PhD, vice president of clinical development at VIVUS, presented the additional data from the company's two year-long phase 3 obesity trials during the Pharmacotherapy Update portion of the pre-conference on October 24, 2009.
› Verified 8 days ago
Quality Life Services - New Castle Location: 520 Friendship Street, New Castle, Pennsylvania 16101 Phone: (412) 654-7791 | |
Grove At New Castle, The Location: 715 Harbor Street, New Castle, Pennsylvania 16101 Phone: (724) 652-3863 | |
Edison Manor Nursing & Rehabilitation Center Location: 222 West Edison Avenue, New Castle, Pennsylvania 16101 Phone: (724) 652-6340 | |
Jameson Care Center Location: 3349 Wilmington Road, New Castle, Pennsylvania 16105 Phone: (724) 598-3300 | |
Haven Convalescent Home, Inc Location: 725 Paul Street, New Castle, Pennsylvania 16101 Phone: (724) 654-8833 |